Lilly’s Donanemab Hit with Surprise Delay, Set to Face FDA Adcomm

Eli Lilly on Friday announced that the FDA has decided to hold an advisory committee meeting to discuss its investigational Alzheimer’s disease antibody donanemab, pushing its target action date to beyond the first quarter of 2024.